Here, we report a strategy for the design of an inexpensive paper analytical device (PAD) for quantitative detection of oligonucleotides and proteins. Detection is based on the principle of target-induced conformational switching of an aptamer linked to an electrochemical label. This simple and robust method is well matched to the equally simple and robust characteristics of the PAD platform. The demonstrated limits of detection for DNA and thrombin are 30 nM and 16 nM, respectively, and the device-to-device reproducibility is better than ±10%. The PAD has a shelf life of at least 4 weeks, involves little user intervention, and requires a sample volume of just 20 μL.

Here we report a sensing scheme for detection of microRNA (miRNA) using electrocatalytic amplification (ECA). ECA is a method in which nanoparticles (NPs) that are catalytic for a specific electrochemical reaction collide with an inert electrode surface. Each collision results in a detectable current transient. In the present article, we show that this general approach can be extended to detection of miRNA. Specifically, PtNPs are modified with a single-strand DNA (ssDNA) shell that is complementary to the miRNA target. Next, the ssDNA:miRNA conjugate is formed, which passivates the PtNP surface. In the presence of an enzyme called duplex specific nuclease (DSN), however, a fraction of the surface-bound DNA is removed thereby exposing some of the PtNP surface. In other words, the electrocatalytic properties of the PtNPs are reactivated only if miRNA complementary to ssDNA is present. This methodology resolves a number of problems that have rendered ECA ineffective for biosensing applications. Moreover, the results suggest that the underlying chemistry is broadly applicable to nucleic acid sensing.

Background and Objective Nanotechnology offers the possibility of creating multi-functional structures that can provide solutions for biomedical problems. The nanoprobes herein described are an example of such structures, where nanoprobes have been designed to provide high specificity and contrast potential for optical detection of cancer. Specifically, enzymatically activated fluorescent nanoprobes (EANPs) were synthesized as cancer-specific contrast agents for optical imaging. Study Design/Materials and Methods EANPs were prepared by nanoprecipitation of blends of poly(lactic acid)-b-poly(ethylene glycol) and poly(lactic-co-glycolic acid)-b-poly(L-lysine). The lysine moieties were then covalently decorated with the near infrared (NIR) fluorescent molecule AlexaFluor-750 (AF750). Close proximity of the fluorescent molecules to each other resulted in fluorescence quenching, which was be reversed by enzymatically mediated cleavage of poly(L-lysine) chains. EANPs were characterized by dynamic light scattering and electron microscopy. Enzymatic development of fluorescence was studied in vitro by fluorescence spectroscopy. Biocompatibility and contrast potential of EANPs were studied in cancerous and noncancerous cells. The potential of the nanoprobes as contrast agents for NIR fluorescence imaging was studied in tissue phantoms. Results Spherical EANPs of ∼100 nm were synthesized via nanoprecipitation of polymer blends. Fluorescence activation of EANPs by treatment with a model protease was demonstrated with up to 15-fold optical signal enhancement within 120 minutes. Studies with MDA-MB-231 breast cancer cells demonstrated the cytocompatibility of EANPs, as well as enhanced fluorescence associated with enzymatic activation. Imaging studies in tissue phantoms confirmed the ability of a simple imaging system based on a laser source and CCD camera to image dilute suspensions of the nanoprobe at depths of up to 4 mm, as well as up to a 13-fold signal-to-background ratio for enzymatically activated EANPs compared to un-activated EANPs at the same concentration. Conclusion Nanoprecipitation of copolymer blends containing poly(L-lysine) was utilized as a method for preparation of highly functional nanoprobes with high potential as contrast agents for fluorescence based imaging of cancer.

No abstract